Ionis Pharmaceuticals, Inc.

LSE:0JDI Stock Report

Market Cap: US$6.0b

Ionis Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Ionis Pharmaceuticals's earnings have been declining at an average annual rate of -45%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 5.6% per year.

Key information

-45.0%

Earnings growth rate

-44.8%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate-5.6%
Return on equity-138.7%
Net Margin-45.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ionis Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0JDI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24813-3662390
31 Mar 24777-3852200
31 Dec 23788-3662130
30 Sep 23615-4092100
30 Jun 23631-3091740
31 Mar 23576-3291620
31 Dec 22587-2701500
30 Sep 2287571410
30 Jun 22849-281370
31 Mar 22841-41480
31 Dec 21810-291860
30 Sep 21661-6082070
30 Jun 21688-5502450
31 Mar 21708-4952720
31 Dec 20729-4443540
30 Sep 20933942990
30 Jun 209401452900
31 Mar 209591692930
31 Dec 191,1232812870
30 Sep 198214332690
30 Jun 197994022780
31 Mar 197523662690
31 Dec 186002772450
30 Sep 18575-412240
30 Jun 18548-381820
31 Mar 1854391380
31 Dec 17514191080
30 Sep 1750742810
30 Jun 1749952640
31 Mar 17426-15520
31 Dec 16373-60490
30 Sep 16238-184440
30 Jun 16176-227420
31 Mar 16258-134400
31 Dec 15284-88370
30 Sep 1531714310
30 Jun 1531223270
31 Mar 15249-24230
31 Dec 14214-39200
30 Sep 14172-94180
30 Jun 14151-92170
31 Mar 14132-90160
31 Dec 13147-61150

Quality Earnings: 0JDI is currently unprofitable.

Growing Profit Margin: 0JDI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0JDI is unprofitable, and losses have increased over the past 5 years at a rate of 45% per year.

Accelerating Growth: Unable to compare 0JDI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0JDI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).


Return on Equity

High ROE: 0JDI has a negative Return on Equity (-138.7%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies